NO981146L - Transcytotiske midler og forsterkere for medikamentleveranser - Google Patents
Transcytotiske midler og forsterkere for medikamentleveranserInfo
- Publication number
- NO981146L NO981146L NO981146A NO981146A NO981146L NO 981146 L NO981146 L NO 981146L NO 981146 A NO981146 A NO 981146A NO 981146 A NO981146 A NO 981146A NO 981146 L NO981146 L NO 981146L
- Authority
- NO
- Norway
- Prior art keywords
- transcytotic
- enhancers
- agents
- drug delivery
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US409795P | 1995-09-21 | 1995-09-21 | |
| GBGB9606315.1A GB9606315D0 (en) | 1996-03-26 | 1996-03-26 | Transcytosis vehicles and enhancers for drug delivery |
| PCT/GB1996/002326 WO1997010850A1 (en) | 1995-09-21 | 1996-09-20 | Transcytosis vehicles and enhancers for drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO981146D0 NO981146D0 (no) | 1998-03-16 |
| NO981146L true NO981146L (no) | 1998-03-16 |
Family
ID=26308989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO981146A NO981146L (no) | 1995-09-21 | 1998-03-16 | Transcytotiske midler og forsterkere for medikamentleveranser |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6204054B1 (ru) |
| EP (1) | EP0851767A1 (ru) |
| JP (1) | JPH11512451A (ru) |
| KR (1) | KR19990063632A (ru) |
| CN (1) | CN1195995A (ru) |
| AU (1) | AU717329B2 (ru) |
| BR (1) | BR9610492A (ru) |
| CA (1) | CA2230479A1 (ru) |
| CZ (1) | CZ50398A3 (ru) |
| HU (1) | HUP9900017A3 (ru) |
| NO (1) | NO981146L (ru) |
| NZ (1) | NZ318472A (ru) |
| PL (1) | PL326078A1 (ru) |
| RU (1) | RU2169010C2 (ru) |
| WO (1) | WO1997010850A1 (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
| US20070117863A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6165976A (en) | 1994-06-23 | 2000-12-26 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| DE69530519T2 (de) | 1994-12-22 | 2004-03-04 | Astrazeneca Ab | Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation |
| US6261787B1 (en) * | 1996-06-03 | 2001-07-17 | Case Western Reserve University | Bifunctional molecules for delivery of therapeutics |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| AU741528B2 (en) | 1997-06-05 | 2001-12-06 | Hemosphere, Inc. | Fibrinogen-coated microspheres |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| GB9801070D0 (en) * | 1998-01-19 | 1998-03-18 | Andaris Ltd | HIV inhibition |
| WO2001074400A1 (fr) * | 2000-04-03 | 2001-10-11 | Santen Pharmaceutical Co., Ltd. | Transporteurs et systeme de distribution de medicament les utilisant |
| WO2002032396A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for delivery of nucleic acids |
| AU2002210383A1 (en) * | 2000-10-16 | 2002-04-29 | Proteopharma Aps | The function of a haptoglobin-haemoglobin receptor and the uses thereof |
| EP1355941A2 (en) * | 2001-02-02 | 2003-10-29 | ConjuChem, Inc. | Long lasting growth hormone releasing factor derivatives |
| WO2003000711A1 (en) * | 2001-06-22 | 2003-01-03 | The University Of British Columbia | Antimitotic eleuthesides |
| KR20040039428A (ko) * | 2001-09-28 | 2004-05-10 | 산텐 세이야꾸 가부시키가이샤 | 약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제 |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1465869B1 (en) * | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| RU2361615C2 (ru) * | 2002-12-09 | 2009-07-20 | Абраксис Байосайенс, Ллс. | Композиции и способы доставки фармакологических агентов |
| MXPA05006169A (es) * | 2002-12-09 | 2006-03-30 | American Biosciences | Composiciones y metodos para el suministro de agentes farmacologicos. |
| EP2239273B1 (en) * | 2003-11-13 | 2013-10-09 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprosing an immunoglobulin fc as a carrier |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US7666991B2 (en) * | 2005-12-05 | 2010-02-23 | Trinity Biosystems, Inc. | Compositions for needleless delivery of antibodies |
| EP2253326B1 (en) * | 2008-02-28 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for transnasal administration |
| US20100166808A1 (en) * | 2008-11-17 | 2010-07-01 | Giovanni Marco Pauletti | Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands |
| AU2009322145A1 (en) * | 2008-12-05 | 2011-06-23 | Abraxis Bioscience, Llc | SPARC Binding ScFvs |
| US9127079B2 (en) | 2009-10-16 | 2015-09-08 | The University Of British Columbia | Inhibitors of phosphatase and tensin homolog (PTEN) conjugates |
| JP5818319B2 (ja) | 2009-12-14 | 2015-11-18 | 国立大学法人北海道大学 | 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体 |
| BR112013006088B1 (pt) * | 2010-09-15 | 2022-06-14 | Randall J Mrsny | Construto de entrega isolado, e, composição farmacêutica |
| WO2014197546A1 (en) * | 2013-06-04 | 2014-12-11 | The Johns Hopkins University | Therapeutic strategy via controllable transepithelial delivery of therapeutics and diagnostics |
| CA2959660A1 (en) | 2014-09-03 | 2016-03-10 | Genesegues, Inc. | Therapeutic nanoparticles and related compositions, methods, and systems |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993020834A1 (en) * | 1992-04-10 | 1993-10-28 | Brigham And Women's Hospital | Methods and compositions for oral delivery of therapeutic agents |
-
1996
- 1996-09-20 BR BR9610492A patent/BR9610492A/pt unknown
- 1996-09-20 WO PCT/GB1996/002326 patent/WO1997010850A1/en not_active Application Discontinuation
- 1996-09-20 CZ CZ98503A patent/CZ50398A3/cs unknown
- 1996-09-20 NZ NZ318472A patent/NZ318472A/en unknown
- 1996-09-20 RU RU98107656/14A patent/RU2169010C2/ru not_active IP Right Cessation
- 1996-09-20 CA CA002230479A patent/CA2230479A1/en not_active Abandoned
- 1996-09-20 PL PL96326078A patent/PL326078A1/xx unknown
- 1996-09-20 HU HU9900017A patent/HUP9900017A3/hu unknown
- 1996-09-20 CN CN96196859A patent/CN1195995A/zh active Pending
- 1996-09-20 JP JP9512490A patent/JPH11512451A/ja active Pending
- 1996-09-20 KR KR1019980702081A patent/KR19990063632A/ko not_active Application Discontinuation
- 1996-09-20 EP EP96931162A patent/EP0851767A1/en not_active Withdrawn
- 1996-09-20 AU AU69957/96A patent/AU717329B2/en not_active Ceased
- 1996-09-20 US US09/043,412 patent/US6204054B1/en not_active Expired - Fee Related
-
1998
- 1998-03-16 NO NO981146A patent/NO981146L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9900017A3 (en) | 2001-08-28 |
| PL326078A1 (en) | 1998-08-17 |
| NZ318472A (en) | 1999-10-28 |
| HUP9900017A2 (hu) | 1999-04-28 |
| MX9802286A (es) | 1998-08-30 |
| CN1195995A (zh) | 1998-10-14 |
| JPH11512451A (ja) | 1999-10-26 |
| EP0851767A1 (en) | 1998-07-08 |
| WO1997010850A1 (en) | 1997-03-27 |
| NO981146D0 (no) | 1998-03-16 |
| KR19990063632A (ko) | 1999-07-26 |
| AU717329B2 (en) | 2000-03-23 |
| AU6995796A (en) | 1997-04-09 |
| BR9610492A (pt) | 1999-03-30 |
| US6204054B1 (en) | 2001-03-20 |
| CA2230479A1 (en) | 1997-03-27 |
| CZ50398A3 (cs) | 1998-07-15 |
| RU2169010C2 (ru) | 2001-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO981146D0 (no) | Transcytotiske midler og forsterkere for medikamentleveranser | |
| DK1009454T3 (da) | Dental bedövelsesmiddel og tilförselsinjektionsenhed | |
| BR9610153A (pt) | Formulações farmacêuticas | |
| BR9611626A (pt) | Formulações farmacéuticas | |
| DE69620549D1 (de) | Intravaginale Freisetzungsvorrichtung für Medikamente | |
| NO982613D0 (no) | Legemiddelavleveringsanordning | |
| LU91138I2 (fr) | Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables. | |
| BR9607851B1 (pt) | combinaÇço e formulaÇço farmacÊutica. | |
| DE69816325D1 (de) | Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport | |
| DE69531788D1 (de) | Verbessertes bioadhäsives pharmazeutisches abgabesystem | |
| NO20000735L (no) | Legemiddel leveringsanordning for vedvarende frigivelse | |
| NO943358D0 (no) | Elektrokjemisk fremgangsmåte og innretning for tilförsel av legemiddel | |
| FI971279A (fi) | Lääkkeitä | |
| BR9607317A (pt) | Peptídios e composição farmacêutica | |
| BR9607318A (pt) | Peptidos e composição farmacêutica | |
| NO994837D0 (no) | Intravesikal medikamentavleveringssystem | |
| ID23874A (id) | Obat | |
| DE69828895D1 (de) | Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen | |
| NO980546D0 (no) | Farmasöytiske midler | |
| DE69430699D1 (de) | Medikamente abgebende stents | |
| BR9509688A (pt) | Composto e composição farmacêutica | |
| FI943201A (fi) | Vaikuttavaa ainetta luovuttava laite | |
| NO20002526D0 (no) | Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav | |
| EE9800275A (et) | Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid | |
| BR9606066A (pt) | Composto e formulação farmacêutica |